Aytu BioPharma Management

Management criteria checks 2/4

Aytu BioPharma's CEO is Josh Disbrow, appointed in Apr 2015, has a tenure of 7.25 years. total yearly compensation is $567.31K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.61% of the company’s shares, worth €123.42K. The average tenure of the management team and the board of directors is 0.4 years and 6.9 years respectively.

Key information

Josh Disbrow

Chief executive officer

US$567.3k

Total compensation

CEO salary percentage	100.0%
CEO tenure	8yrs
CEO ownership	1.6%
Management average tenure	less than a year
Board average tenure	6.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Josh Disbrow's remuneration changed compared to Aytu BioPharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	n/a	n/a	-US$78m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	US$567k	US$567k	-US$110m
Mar 31 2022	n/a	n/a	-US$111m
Dec 31 2021	n/a	n/a	-US$84m
Sep 30 2021	n/a	n/a	-US$82m
Jun 30 2021	US$6m	US$545k	-US$58m
Mar 31 2021	n/a	n/a	-US$42m
Dec 31 2020	n/a	n/a	-US$22m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	US$2m	US$608k	-US$14m
Mar 31 2020	n/a	n/a	-US$25m
Dec 31 2019	n/a	n/a	-US$24m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	US$1m	US$330k	-US$27m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$10m
Sep 30 2018	n/a	n/a	-US$9m
Jun 30 2018	US$606k	US$303k	-US$10m
Mar 31 2018	n/a	n/a	-US$17m
Dec 31 2017	n/a	n/a	-US$20m
Sep 30 2017	n/a	n/a	-US$21m
Jun 30 2017	US$1m	US$250k	-US$23m
Mar 31 2017	n/a	n/a	-US$31m
Dec 31 2016	n/a	n/a	-US$33m
Sep 30 2016	n/a	n/a	-US$32m
Jun 30 2016	US$1m	US$250k	-US$28m

Compensation vs Market: Josh's total compensation ($USD567.31K) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Josh's compensation has been consistent with company performance over the past year.

CEO

Josh Disbrow (47 yo)

8yrs

Tenure

US$567,308

Compensation

Mr. Joshua R. Disbrow, also known as Josh, is Chairman of the Board at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 and serves as its Chief Executive Officer. He serves as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Joshua Disbrow	Chairman & CEO	8yrs	US$567.31k	1.61% $ 123.4k
Mark Oki	CFO, Secretary & Treasurer	1.3yrs	US$352.60k	0.27% $ 20.4k
Christopher Brooke	Chief Operating Officer	less than a year	no data	1.63% $ 125.1k
Victoria Cordova	Vice President of People & Culture	less than a year	no data	no data
Jarrett Disbrow	Chief Business Officer & President of Consumer Health	less than a year	US$793.41k	0.36% $ 27.4k
Greg Pyszczymuka	Chief Commercial Officer	no data	no data	0.25% $ 19.5k
Russ McMahen	Senior Vice President of Research & Development	no data	no data	no data
Ryan Selhorn	Executive VP of Finance & Business Optimization	less than a year	no data	no data

0.4yrs

Average Tenure

47yo

Average Age

Experienced Management: AY20's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Joshua Disbrow	Chairman & CEO	7.3yrs	US$567.31k	1.61% $ 123.4k
Vivian Liu	Independent Director	less than a year	no data	0.19% $ 14.6k
John Donofrio	Lead Independent Director	6.8yrs	US$75.00k	0.021% $ 1.6k
Carl Dockery	Independent Director	7yrs	US$70.00k	0.21% $ 15.9k

6.9yrs

Average Tenure

57yo

Average Age

Experienced Board: AY20's board of directors are considered experienced (6.9 years average tenure).

Aytu BioPharma Management

Management criteria checks 2/4

Key information

Recent management updates

Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of Directors

Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022

Aytu BioPharma, Inc. Announces the Passing of Michael Macaluso, Board Member

Aytu BioPharma, Inc. Announces Management Changes

Aytu Biopharma, Inc. Appoints Vivian Liu to Its Board of Directors and as Member of the Nominating & Corporate Governance Committee, Effective July 1, 2022

Insufficient new directors

Recent updates

Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024

Aytu BioPharma, Inc. to Report Q2, 2024 Results on Feb 14, 2024

Aytu BioPharma, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. announced delayed annual 10-K filing

Aytu BioPharma, Inc. to Report Q4, 2023 Results on Sep 27, 2023

Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million.

Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of Directors

Aytu BioPharma, Inc. announced delayed 10-Q filing

Aytu BioPharma, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Aytu Biopharma Regains Nasdaq Minimum Bid Price Compliance

Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients

Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022

Aytu BioPharma Receives A 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Aytu BioPharma, Inc. Announces the Passing of Michael Macaluso, Board Member

First quarter 2023 earnings released: US$0.057 loss per share (vs US$1.09 loss in 1Q 2022)

Forecast to breakeven in 2025

Aytu BioPharma, Inc. Announces Management Changes

Aytu BioPharma, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Aytu Biopharma Announces Continuing Availability of Adhd Medication Adzenys Xr-Odt(R) in Response to Reported Generic Adderall(R) Xr Supply Disruptions

Full year 2022 earnings released: US$3.75 loss per share (vs US$3.48 loss in FY 2021)

Aytu BioPharma, Inc. to Report Q4, 2022 Results on Sep 27, 2022

Aytu BioPharma, Inc. Announces Addition of Fourth Patent License for Ar101/Enzastaurin

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu Biopharma, Inc. Appoints Vivian Liu to Its Board of Directors and as Member of the Nominating & Corporate Governance Committee, Effective July 1, 2022

Aytu BioPharma Receives Letter from the Nasdaq

Third quarter 2022 earnings released: US$1.79 loss per share (vs US$1.41 loss in 3Q 2021)

Insufficient new directors

Aytu BioPharma, Inc., Annual General Meeting, May 18, 2022

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

First quarter 2022 earnings released: US$1.09 loss per share (vs US$0.35 loss in 1Q 2021)

Full year 2021 earnings released: US$3.48 loss per share (vs US$3.01 loss in FY 2020)

Forecast to breakeven in 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

Independent Director Steven Boyd has left the company

Aytu Biopharma, Inc.(NasdaqCM:AYTU) dropped from Russell 3000E Value Index

Aytu Biopharma, Inc. Plans to Close Grand Prairie, Texas Manufacturing Operations over the Next Eighteen Months

CFO, Secretary & Treasurer has left the company

Independent Director has left the company

Second quarter 2021 earnings released: US$0.72 loss per share (vs US$0.12 loss in 2Q 2020)

Revenue beats expectations

Aytu BioScience, Inc. (NasdaqCM:AYTU) entered into definitive merger agreement to acquire Neos Therapeutics, Inc. (NasdaqGM:NEOS) for $37.8 million.

Aytu BioScience, Inc. to Report Q1, 2021 Results on Nov 12, 2020

Aytu BioScience, Inc. to Report Q4, 2020 Results on Oct 06, 2020

Aytu BioScience, Inc. announced delayed annual 10-K filing

New 90-day low - €0.86

New 90-day low - €1.10

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age